🇺🇸 FDA
Pipeline program

lamivudine

MOH-02

Approved small_molecule completed

Quick answer

lamivudine for Compensated Chronic Hepatitis B is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Compensated Chronic Hepatitis B
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials